This Week in Peptide Research: Orforglipron's First Cardiovascular Safety Data, Multi-Agonist Pipeline Papers, and a Setmelanotide Correspondence

Peptide Science Daily reviewed new PubMed listings for its tracked compounds from October 12 through October 18, 2026. The week's most significant publication was a pair of linked papers in the Lancet reporting the first dedicated cardiovascular-outcomes trial of a non-peptide, oral GLP-1 receptor agonist. Three more papers examined the broader multi-receptor-agonist pipeline, the New England Journal of Medicine ran a correspondence exchange on a trial Peptide Science Daily covered earlier this year, and a detection-science paper addressed a peptide prohibited in sport.

ACHIEVE-4, run by Eli Lilly and published in the Lancet, randomized 2,749 adults with type 2 diabetes, a BMI of 25 or higher, and established cardiovascular or chronic kidney disease to oral orforglipron (up to a 36 mg capsule once daily) or injectable insulin glargine, both added to existing glucose-lowering therapy, at 317 sites in 16 countries and territories between May 2023 and September 2024. Over a median follow-up of two years, the trial's primary four-component composite of cardiovascular death, non-fatal heart attack, non-fatal stroke, or hospitalization for unstable angina occurred in 4.2 percent of orforglipron participants versus 5.0 percent of insulin glargine participants, meeting the trial's prespecified statistical threshold for non-inferiority (hazard ratio 0.84, 95 percent CI 0.59 to 1.20). Clinically significant or severe hypoglycemia was less frequent with orforglipron (6.8 percent) than with insulin glargine (19.2 percent), and fewer participants died in the orforglipron group (19 of 1,371) than in the insulin glargine group (43 of 1,355), though nearly all deaths in both arms were judged unrelated to treatment. Gastrointestinal adverse events, the most common reason participants stopped orforglipron, were far more frequent with orforglipron (62.1 percent) than with insulin glargine (14.2 percent). The same Lancet issue carried a companion comment article from physicians at Harvard Medical School and Ruhr-University-Bochum, Germany, discussing the trial's implications for establishing cardiovascular safety of non-peptide GLP-1 drugs. Orforglipron, sold as Foundayo, is FDA-approved for chronic weight management as of April 2026 but is not yet approved for type 2 diabetes; ACHIEVE-4 supplies safety data relevant to that pending indication rather than a new approval.

Three more papers this week examined multi-receptor agonists beyond orforglipron. In Diabetes, Obesity and Metabolism, a Tianjin Medical University team reported that mazdutide, a dual GLP-1/glucagon receptor agonist approved in China for weight management and type 2 diabetes, reduced liver fat accumulation and circulating cholesterol in mice with metabolic dysfunction-associated steatotic liver disease; the finding comes from an animal model and has not been tested in a dedicated human liver-disease trial. In the same journal, a nephrologist at the Affiliated Hospital of Yanbian University published an invited commentary posing the open question of whether survodutide, an investigational GLP-1/glucagon dual agonist still in phase 3 testing for obesity and MASH, might protect the kidneys through a mechanism independent of its effects on weight and blood pressure; the piece is a perspective article, not a new clinical dataset. In the Journal of Clinical Endocrinology and Metabolism, an Eli Lilly team published a post-hoc metabolomics and lipidomics analysis of two completed phase 2 trials of retatrutide, the investigational triple GIP/GLP-1/glucagon receptor agonist, in a combined 495 participants with obesity, with and without type 2 diabetes. Higher retatrutide doses were associated with changes in a cluster of fat-metabolism markers (including 3-hydroxybutyrate and several acylcarnitines) that the authors calculated accounted for 23.2 percent of weight loss in participants without diabetes and 12.7 percent in participants with diabetes, alongside separate changes in markers linked to insulin resistance; the analysis is exploratory and does not establish that these markers caused the weight change.

Rounding out the theme, a narrative review in the Journal of Diabetes and Metabolic Disorders, from authors at UCSI University in Malaysia and several Chinese institutions, surveyed the history of pediatric anti-obesity pharmacotherapy. The review noted that earlier weight-loss drugs for any age group, including fenfluramine, sibutramine, and rimonabant, were withdrawn after serious safety problems emerged, and that GLP-1 receptor agonists such as semaglutide and the dual-target agonist tirzepatide have since gained use in adolescents with obesity, though long-term neurodevelopmental safety data in that age group remain limited. The authors suggested that multi-target drugs including mazdutide and the investigational retatrutide are likely to be focal points of future pediatric obesity drug research, while emphasizing an urgent need for dedicated pediatric trials of any such therapy before its use in children becomes standard.

The New England Journal of Medicine published a correspondence exchange on the TRANSCEND trial of setmelanotide in acquired hypothalamic obesity, the study Peptide Science Daily covered when NEJM first published it in July 2026. Two separate letters, one from clinicians in Shanghai and one from clinicians in Changsha, China, commented on the original trial report, and TRANSCEND investigators Christian Roth and Jennifer Miller published a reply. PubMed does not index an abstract for any of the three pieces, only their titles and author lists, so the specific points raised in the letters and the reply are not detailed here. Setmelanotide, sold as Imcivree, is FDA-approved for acquired hypothalamic obesity, an indication the TRANSCEND trial supported.

One further paper addressed detection rather than treatment. Scientists at Racing Analytical Services in Victoria, Australia, developed and validated an ELISA assay that detects CJC-1295, a long-acting growth hormone-releasing hormone analog, in horse blood plasma at concentrations as low as 12.5 picograms per milliliter, and demonstrated the assay on blood drawn from thoroughbred racehorses after they were given the compound. CJC-1295 has never been approved for human or animal clinical use and is prohibited in human sport by the World Anti-Doping Agency; the paper's stated purpose was controlling illicit use of the compound in horseracing, not any therapeutic application.

This week's coverage spans the first cardiovascular-outcomes trial of a non-peptide GLP-1 drug, three papers on the mechanistic and exploratory landscape of multi-receptor agonists, a correspondence exchange over an already-approved rare-obesity therapy, and a veterinary anti-doping detection method for a prohibited peptide. Orforglipron, mazdutide (in China), semaglutide, tirzepatide, and setmelanotide are approved drugs for at least one indication in at least one jurisdiction; survodutide and retatrutide remain investigational with no FDA, EMA, or TGA approval for any use; CJC-1295 remains unapproved everywhere and prohibited in sport. As with all research covered here, these are findings each study, review, or correspondence described, not established clinical fact or treatment guidance.